<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931138</url>
  </required_header>
  <id_info>
    <org_study_id>ALFA 9801</org_study_id>
    <nct_id>NCT00931138</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2</brief_title>
  <acronym>ALFA 9801</acronym>
  <official_title>Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acute Leukemia French Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acute Leukemia French Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison of standard induction treatment with daunorubicin for 3 days and
      Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of
      maintenance treatment with IL2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 50 to 70 years with de novo AML were randomized to receive ARAC 200 mg / m² / d
      IV x 7 d with either DNR 80 mg/m²/dx3d (arm 1) or IDA 12 mg / m²/d x 3 d (arm 2) or 4 d (arm
      3). The pts received a failing course of remedial Mitoxantrone involving x 2 and j ARAC 1g /
      m 2 x / d x 4 days The pts in CR then received 2 courses of consolidation with, according to
      initial randomization either DNR 80 mg / m² IDA 12 mg / sqm x 1 d (1st treatment) or 2 d (2nd
      treatment) and ARAC 1 gsm 2/jx x 4 days The pts in CR were then randomized persistent IL2 (5
      million IU / m² x 5 d / month in SC for 12 months) or no treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare idarubicin versus daunorubicin: the duration of the event-free survival (EFS) to compare IL2 versus abstention : the relapse rate assessed during the first year following the start of maintenance treatment with interleukin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>420</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm1 = Aracytine + Daunorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 = Aracytine And Idarubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 = Aracytine And Idarubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy (Aracytine + Daunorubicin)</intervention_name>
    <description>Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3</description>
    <arm_group_label>Arm1 = Aracytine + Daunorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy (Aracytine + Daunorubicin)</intervention_name>
    <description>Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3</description>
    <arm_group_label>Arm 2 = Aracytine And Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy (Aracytine + Daunorubicin)</intervention_name>
    <description>Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4</description>
    <arm_group_label>Arm 3 = Aracytine And Idarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient from 50 to 70 years

          -  AML de Novo

          -  No prior therapy for AML

          -  Absence of severe infection (WHO grade greater than 2), independent of the AML

          -  Cardiac function determined by radionucleotide or echography within normal limits.

          -  total bilirubin less than or equal 2N and Serum creatinin less than or equal 2N

          -  ECOG performance status 0 to 3

          -  Signed informed consent.

        Exclusion Criteria:

          -  M3-AML

          -  history of neoplasia treated by radiotherapy or chemotherapy

          -  Myelodysplasia diagnosed more than 6 months before the diagnosis of AML

          -  Prior treatment for AML

          -  Uncontrolled infection

          -  Other active malignancy

          -  Patient unable to undergo regular surveillance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNLCC</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>June 30, 2009</last_update_submitted>
  <last_update_submitted_qc>June 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Sylvie Castaigne - Pricipal Investigator</name_title>
    <organization>CHV A. MIGNOT</organization>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia in adults</keyword>
  <keyword>Newly-diagnosed untreated AML</keyword>
  <keyword>Patient aged 50 to 70 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

